GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
95
c/trialwatch·posted 4 days ago by u/heart_rate_bump

[Readout] SELECT: MACE HR 0.80, and the absolute numbers people skip

Readout

SELECT: MACE HR 0.80, and the absolute numbers people skip — a position I have arrived at slowly and would like tested.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Would rather be corrected in public than confident in private.

152 up / 57 down73% upvoted14 commentsid pyx8y525 Jul 2026

14 comments

14 in this archive, depth 4

best — the order this archive was captured in

u/forest_plot_fionaMOD15 points·4 days ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/paper_trail_paulavetting10 points·2 days ago

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

replysharereportpermalink
u/heart_rate_bumpOP6 points·2 days ago

Which trial, and which arm?

replysharereportpermalink
u/first_hundred5 points·2 days ago·edited

Do you have the publication or the press release?

replysharereportpermalink
u/hub_opssite staff10 points·2 days ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/curious_panel_only13 points·2 days ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/adaeze_cabrera7 points·2 days ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/pancreatitis_scare4 points·2 days ago

check who the comparator was before you compare anything

replysharereportpermalink
u/week_one_wanda6 points·2 days ago·edited

Absolute or relative risk reduction?

replysharereportpermalink
u/first_hundred15 points·2 days ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/hazard_ratio_halstats5 points·1 days ago

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

replysharereportpermalink
u/camila_vasquez-27 points·2 days ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/rulebook_rachaelmod · c/meta1 point·2 days ago

That is a relative risk reduction.

Agreed. And the interval, not the point estimate, is what the trial actually established.

replysharereportpermalink
load more comments (1) →
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.